CDH17 and pachyonychia congenita: Aberrant expression of CDH17 has been reported in a number of cancers including GC [13, 30], CRC [15, 36], esophageal cancer [37], hepatocellular carcinoma (HCC) [38], pancreatic cancer (PC) [37] and neuroendocrine tumor (NET) [17].